Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

GA or NZ in RRMS patients is associated with increased benefits compared with symptom management, albeit at higher costs. Although year 1 and 2 disease progression and relapse rates were better for NZ than GA, long-term evidence may show GA to have similar, if not improved, clinical benefit. </AbstractSection> Copyright Adis Data Information BV 2009

MoreLess

Year of publication:	2009
Authors:	Earnshaw, Stephanie ; Graham, Jonathan ; Oleen-Burkey, MerriKay ; Castelli-Haley, Jane ; Johnson, Kenneth
Published in:	Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 7.2009, 2, p. 91-108
Publisher:	Springer

Online Resource

Check full text access |

More access options

Check Google Scholar

In libraries world-wide (WorldCat)

In German libraries (KVK)

subito order

I need help

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011000855